=?iso-8859-1?q?Une_revue_des_connaissances_actuelles_en_mati= E8re_de_cellules_tumorales_mammaires_diss=E9min=E9 es_dans_l'organisme.?=

18 oktober 2006, 13:15

Significance, detection and markers of disseminated breast cancer
cells.
par Marc Lacroix
InTextoResearch, Baelen, Wallonie, Belgique & Institut Jules Bordet,
Bruxelles, Belgique
dans Endocrine-Related Cancer (sous presse)

http://www.geocities.com/m.lacroix/erc3.htm
http://journals.endocrinology.org/erc/fca/ERC00001.htm

The development of distant metastases is the major cause of death from
breast cancer. In order to predict and prevent tumour spreading, many
attempts are being made to detect small numbers of tumour cells that
have shed from the primary lesions and have moved to lymph nodes, blood
or bone marrow. This review presents the advantages and limitations of
techniques used for disseminated tumour cells (DTC) detection in breast
cancer. DTC markers are listed and the most currently used of them
(KRT19, CEACAM5/CEA, TACSTD1/GA733-2/TROP1/M4S1, MUC1, EGFR, ERBB2,
SCGB2A2/MAMMAGLOBIN, SCGB2A1/MAMMAGLOBIN2, SCGB1D2, PIP/GCDFP15, SBEM,
TFF1/pS2, TFF3, ANKRD30A/NY-BR-1, SPDEF/PDEF, ESR1, SERPINB5/MASPIN,
and GABRP) are discussed, notably on the basis of recent data on breast
tumour portraits ("luminal epithelial-like",
"basal/myoepithelial-like" and "ERBB2/Her2/neu"). The
significance of DTC for prognosis and prediction of response to therapy
is examined. DTC viability, the notion of cell dormancy and the concept
of breast cancer stem cells are also discussed.

18 oktober 2006, 13:15	#1
[email protected] Berichten: n/a	=?iso-8859-1?q?Une_revue_des_connaissances_actuelles_en_mati= E8re_de_cellules_tumorales_mammaires_diss=E9min=E9 es_dans_l'organisme.?= Significance, detection and markers of disseminated breast cancer cells. par Marc Lacroix InTextoResearch, Baelen, Wallonie, Belgique & Institut Jules Bordet, Bruxelles, Belgique dans Endocrine-Related Cancer (sous presse) http://www.geocities.com/m.lacroix/erc3.htm http://journals.endocrinology.org/erc/fca/ERC00001.htm The development of distant metastases is the major cause of death from breast cancer. In order to predict and prevent tumour spreading, many attempts are being made to detect small numbers of tumour cells that have shed from the primary lesions and have moved to lymph nodes, blood or bone marrow. This review presents the advantages and limitations of techniques used for disseminated tumour cells (DTC) detection in breast cancer. DTC markers are listed and the most currently used of them (KRT19, CEACAM5/CEA, TACSTD1/GA733-2/TROP1/M4S1, MUC1, EGFR, ERBB2, SCGB2A2/MAMMAGLOBIN, SCGB2A1/MAMMAGLOBIN2, SCGB1D2, PIP/GCDFP15, SBEM, TFF1/pS2, TFF3, ANKRD30A/NY-BR-1, SPDEF/PDEF, ESR1, SERPINB5/MASPIN, and GABRP) are discussed, notably on the basis of recent data on breast tumour portraits ("luminal epithelial-like", "basal/myoepithelial-like" and "ERBB2/Her2/neu"). The significance of DTC for prognosis and prediction of response to therapy is examined. DTC viability, the notion of cell dormancy and the concept of breast cancer stem cells are also discussed.